Page 82 - 《中国药房》2025年20期

tigecycline-associated drug-induced liver injury among Making，2022，42（4）：487-499.
patients in China：a 3-year retrospective study as assessed [15] ZHAO L Q，LENG Y S，HU Y B，et al. Understanding
by the updated RUCAM[J]. Front Pharmacol，2021，12： decision curve analysis in clinical prediction model research
761167. [J]. Postgrad Med J，2024，100（1185）：512-515.
[ 3 ] OLIVEIRA P R，CARVALHO V C，SACONI E S，et al. [16] FAN G J，JIN L，BAI H S，et al. Safety and efficacy of
Tigecycline versus colistin in the treatment of carba- tigecycline in intensive care unit patients based on thera‐
penem-resistant Acinetobacter baumannii complex osteo‐ peutic drug monitoring[J]. Ther Drug Monit，2020，42（6）：
myelitis[J]. J Bone Jt Infect，2020，5（2）：60-66. 835-840.
[ 4 ] 左成淳，许青，李晓宇，等. 替加环素肝功能异常风险的 [17] RELLO J. Pharmacokinetics，pharmacodynamics，safety
回顾性观察研究[J]. 中国医院药学杂志，2024，44（18）： and tolerability of tigecycline[J]. J Chemother，2005，17
2146-2153. （Suppl. 1）：12-22.
[ 5 ] 章越，聂源，朱萱. 生物标志物在药物性肝损伤的应用进 [18] KADOYAMA K，SAKAEDA T，TAMON A，et al.
展[J]. 安徽医科大学学报，2021，56（4）：663-666. Adverse event profile of tigecycline：data mining of the
[ 6 ] GUDNASON H O，BJÖRNSSON H K，GARDARSDOTTIR public version of the U.S. Food and Drug Administration
M，et al. Secondary sclerosing cholangitis in patients with Adverse Event Reporting System[J]. Biol Pharm Bull，
drug-induced liver injury[J]. Dig Liver Dis，2015，47（6）： 2012，35（6）：967-970.
502-507. [19] LEONOR FERNÁNDEZ-MURGA M，PETROV P D，
[ 7 ] BESSONE F，HERNÁNDEZ N，TANNO M，et al. Drug- CONDE I，et al. Advances in drug-induced cholestasis：
induced vanishing bile duct syndrome：from pathogenesis clinical perspectives，potential mechanisms and in vitro
to diagnosis and therapeutics[J]. Semin Liver Dis，2021， systems[J]. Food Chem Toxicol，2018，120：196-212.
41（3）：331-348. [20] LUCENA M I，ANDRADE R J，KAPLOWITZ N，et al.
[ 8 ] 陆伦根，田丽艳，徐铭益，等. 欧洲肝病学会临床实践指 Phenotypic characterization of idiosyncratic drug-induced
南：胆汁淤积性肝病的治疗：3[J]. 肝脏，2010，15（1）： liver injury：the influence of age and sex[J]. Hepatology，
44-48. 2009，49（6）：2001-2009.
[ 9 ] 中华医学会肝病学分会，中华医学会消化病学分会，中 [21] ISABEL LUCENA M，SANABRIA J，GARCÍA-CORTES
华医学会感染病学分会.胆汁淤积性肝病诊断和治疗共 M，et al. Drug-induced liver injury in older people[J]. Lan‐
识：2015[J].实用肝脏病杂志，2016，19（6）：2-12. cet Gastroenterol Hepatol，2020，5（9）：862-874.
[10] National Cancer Institute. Common terminology criteria [22] RE V L，3rd，CARBONARI D M，LEWIS J D，et al. Oral
for adverse events（CTCAE）v5.0[EB/OL].（2017-11-27） azole antifungal medications and risk of acute liver injury，
[2024-07-17]. https：//ctep. cancer. gov/protocolDevelop‐ overall and by chronic liver disease status[J]. Am J Med，
ment/electronic_applications/docs/CTCAE_v5_Quick_ 2016，129（3）：283-291.e5.
Reference_8.5x11.pdf. [23] CHEN T，LI R，CHEN P. Gut microbiota and chemical-
[11] CHALASANI N P，MADDUR H，RUSSO M W，et al. induced acute liver injury[J]. Front Physiol，2021，12：
ACG clinical guideline：diagnosis and management of 688780.
idiosyncratic drug-induced liver injury[J]. Am J Gastroen‐ [24] CHEN Z H，SHI X Y. Adverse events of high-dose tigecy‐
terol，2021，116（5）：878-898. cline in the treatment of ventilator-associated pneumonia
[12] KIM J H. Multicollinearity and misleading statistical results due to multidrug-resistant pathogens[J]. Medicine （Baltimore），
[J]. Korean J Anesthesiol，2019，72（6）：558-569. 2018，97（38）：e12467.
[13] HOO Z H，CANDLISH J，TEARE D. What is an ROC [25] YU Z W，ZHAO Y H，JIN J Y，et al. Prevalence and risk
curve?[J]. Emerg Med J，2017，34（6）：357-359. factors of tigecycline-induced liver injury：a multicenter
[14] SADATSAFAVI M，SAHA-CHAUDHURI P，PETKAU J. retrospective study[J]. Int J Infect Dis，2022，120：59-64.
Model-based ROC curve：examining the effect of case （收稿日期：2025-06-04 修回日期：2025-09-17）
mix and model calibration on the ROC plot[J]. Med Decis （编辑：陈 宏）

· 2560 · China Pharmacy 2025 Vol. 36 No. 20 中国药房 2025年第36卷第20期